Qiming U.S. Ventures Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed January 28, 2025), Qiming U.S. Ventures Management, LLC reported 6 stock positions worth $51.1 million. Its top holding was Jasper Therapeutics (JSPR) at 38.8% of the portfolio, followed by Tourmaline Bio (TRML, 29.4%) and Korro Bio (KRRO, 27.4%). Compared with Q3 2024, it reduced 1. The biggest sale was Hillevax (HLVX, shares −33%).
- Most Recent 13F
- Q3 2025
- Location
- BELLEVUE, WA
- CIK
- 0001909617
- Portfolio Value
- $51.1M (Q4 2024)
- SEC Filing
- 0001104659-25-006699 ↗ filed Jan 28, 2025
Holdings Value
Holdings 6 stocks · $51.1M
| JSPR Jasper Therapeutics Inc. | 38.83% | 928,964 | $19.9M | No change |
| TRML Tourmaline Bio Inc. | 29.41% | 741,691 | $15.0M | No change |
| KRRO Korro Bio Inc. | 27.40% | 368,085 | $14.0M | No change |
| VTYX Ventyx Biosciences Inc. | 1.77% | 412,225 | $903K | No change |
| HLVX Hillevax Inc. | 1.51% | 372,615 | $771K | Reduce -33.3% |
| KZR Kezar Life Sciences Inc. | 1.09% | 82,871 | $557K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| HLVX Hillevax Inc. | Reduce -33.3% | 1.51% | −0.41 |
Portfolio Buys Q3 2024 → Q4 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 4 | $55.6M | TRML, KRRO, JSPR, KZR |
| Q2 2025 | 6 | $23.6M | TRML, JSPR, KRRO, VTYX, HLVX |
| Q1 2025 | 6 | $23.1M | TRML, KRRO, JSPR, HLVX, VTYX |
| Q4 2024 | 6 | $51.1M | JSPR, TRML, KRRO, VTYX, HLVX |
| Q3 2024 | 6 | $51.4M | TRML, JSPR, KRRO, HLVX, VTYX |
| Q2 2024 | 6 | $52.6M | JSPR, KRRO, TRML, HLVX, VTYX |
| Q1 2024 | 6 | $89.7M | KRRO, JSPR, TRML, HLVX, VTYX |